安神通络针刺法治疗躯体形式障碍疗效观察
|
摘要
目的:比较安神通络法与口服黛力新治疗躯体形式疼痛障碍的疗效差异。方法:将60例躯体形式障碍患者随机分为针刺组与西药组,每组30例。针刺组穴取神庭、印堂、水沟、百会、内关、神门、合谷、太冲及近部取穴,1次/d,6次/周;西药组口服黛力新,早晨及中午各1片,两组均连续治疗4周,采用SCL-90(躯体化、抑郁、焦虑三个因子)量表评分评定两组患者的疗效。结果:两组患者治疗后SCL-90总分均较治疗前明显降低(均P<0.05);针刺组治疗后SCL单项分(躯体化)降低幅度明显>西药组(P<0.05)。针刺组愈显率为56.67%,西药组愈显率为27.59%,两者比较差异有统计学意义(P<0.05)。结论:安神通络针刺治疗躯体形式障碍疗效确切,尤其在改善躯体症状方面明显优于西药黛力新。
Objective: To compare the efficacy difference between Anshen Tongluo method and oral administration of deanxit in the treatment of somatoform disorders. Methods: 60 patients with somatization disorder were randomly divided into acupuncture group and western medicine group, 30 cases in each group. The acupuncture group was treated with acupuncture at Shenting(DU24), Yintang(EX-HN3), Shuigou(DU26), Baihui(DU20), Neiguan(PC6), Shenmen(HT7), Hegu(L14), Taichong(LR3) and neighboring point selection, once daily, six times per week. The western medicine group was treated with deanxit, 1 tablet in the morning and noon. After four weeks, the SCL-90 somatic, depression and anxiety factors scale score was used to assess the efficacy of the two groups. Results: The total scores of SCL-90 in the two groups were significantly lower than those before treatment(P<0.05). The reduction of SCL single points(somatization) in the acupuncture group was significantly greater than that in the western medicine group(P<0.05). The cured and markedly effective rate was 56.67% in the acupuncture group and 27.59% in the western medicine group.The difference was statistically significant. Conclusion: Anshen Tongluo acupuncture is effective in the treatment of somatoform disorders, especially for somatic symptoms.
Objective: To compare the efficacy difference between Anshen Tongluo method and oral administration of deanxit in the treatment of somatoform disorders. Methods: 60 patients with somatization disorder were randomly divided into acupuncture group and western medicine group, 30 cases in each group. The acupuncture group was treated with acupuncture at Shenting(DU24), Yintang(EX-HN3), Shuigou(DU26), Baihui(DU20), Neiguan(PC6), Shenmen(HT7), Hegu(L14), Taichong(LR3) and neighboring point selection, once daily, six times per week. The western medicine group was treated with deanxit, 1 tablet in the morning and noon. After four weeks, the SCL-90 somatic, depression and anxiety factors scale score was used to assess the efficacy of the two groups. Results: The total scores of SCL-90 in the two groups were significantly lower than those before treatment(P<0.05). The reduction of SCL single points(somatization) in the acupuncture group was significantly greater than that in the western medicine group(P<0.05). The cured and markedly effective rate was 56.67% in the acupuncture group and 27.59% in the western medicine group.The difference was statistically significant. Conclusion: Anshen Tongluo acupuncture is effective in the treatment of somatoform disorders, especially for somatic symptoms.
引文
[1]秦颖.躯体形式障碍的研究现状[J].国际精神病学杂志,2013,40(2):110-112.
[2]孟凡强,崔玉华,沈渔村,等.综合医院躯体形式障碍临床特点的初步研究[J].中国心理卫生杂志,1999,13(2):67-69.
[3]陈文泽,陈雪芬,张君青,等.躯体化障碍者的治疗及其神经电生理指标的变化研究[J].浙江医学,2016,38(10):688-690.
[4]梁慧荟,胡玉英,莫海珍,等.中西医治疗躯体形式障碍的研究进展[J].湖南中医杂志,2017,33(11):186-188.
[5]中华医学会精神科分会.中国精神障碍分类与诊断标准[M].3版.济南:山东科学技术出版社,2001:108.
[6]张明园.精神科评定量表手册[M].2版.长沙:湖南科学技术出版社,1998:17-27.
[7]林炽甄,郑义侯.郑义侯教授从肝论治躯体化障碍经验[J].四川中医,2017,35(5):8-10.
[8]姚玉芳,胡波.躯体化障碍的临床特征、治疗及临床转归的研究[J].国际精神病学杂志,2011,38(1):10-14.
[9]李宁,叶兰仙.躯体化障碍的发病机制及诊治的研究进展[J].精神医学杂志,2013,26(2):152-153.
[10]龚平原.多巴胺、5-羟色胺和谷氨酸递质系统相关基因与人类认知能力的关系研究[D].西安:西北大学,2010.
[11]高哲石.神经症的临床分类及其药物治疗进展[J].世界临床药物,2009,30(10):625-631.
[12]张松青,陈婷婷.黛力新联合多虑平用于卒中后抑郁患者早期抗抑郁治疗的临床效果观察[J].临床合理用药杂志,2018,11(9):36-37.
[13]闫西鹏,赵颖颖,王凯丽,等.安神解郁汤联合黛力新治疗轻、中度焦虑抑郁症随机平行对照研究[J].实用中医内科杂志,2017,31(2):47-49.
[14]李爱歆,李鹏,李冬,等.黛力新用于心血管神经症80例的临床观察[J].黑龙江医药科学,2018,41(4):38-39,42.
[15]陈乐乐,岳增辉,朱小姗.针刺对单胺类神经递质及相关神经系统疾病的影响[J].辽宁中医药大学学报,2011,13(12):83-85.
[16]吴雪芬,郑雪娜,郭鑫,等.针刺对失眠大鼠5-HT及其受体、HPA轴相关激素影响的研究进展[J].中华中医药学刊,2018,36(1):127-129.
[2]孟凡强,崔玉华,沈渔村,等.综合医院躯体形式障碍临床特点的初步研究[J].中国心理卫生杂志,1999,13(2):67-69.
[3]陈文泽,陈雪芬,张君青,等.躯体化障碍者的治疗及其神经电生理指标的变化研究[J].浙江医学,2016,38(10):688-690.
[4]梁慧荟,胡玉英,莫海珍,等.中西医治疗躯体形式障碍的研究进展[J].湖南中医杂志,2017,33(11):186-188.
[5]中华医学会精神科分会.中国精神障碍分类与诊断标准[M].3版.济南:山东科学技术出版社,2001:108.
[6]张明园.精神科评定量表手册[M].2版.长沙:湖南科学技术出版社,1998:17-27.
[7]林炽甄,郑义侯.郑义侯教授从肝论治躯体化障碍经验[J].四川中医,2017,35(5):8-10.
[8]姚玉芳,胡波.躯体化障碍的临床特征、治疗及临床转归的研究[J].国际精神病学杂志,2011,38(1):10-14.
[9]李宁,叶兰仙.躯体化障碍的发病机制及诊治的研究进展[J].精神医学杂志,2013,26(2):152-153.
[10]龚平原.多巴胺、5-羟色胺和谷氨酸递质系统相关基因与人类认知能力的关系研究[D].西安:西北大学,2010.
[11]高哲石.神经症的临床分类及其药物治疗进展[J].世界临床药物,2009,30(10):625-631.
[12]张松青,陈婷婷.黛力新联合多虑平用于卒中后抑郁患者早期抗抑郁治疗的临床效果观察[J].临床合理用药杂志,2018,11(9):36-37.
[13]闫西鹏,赵颖颖,王凯丽,等.安神解郁汤联合黛力新治疗轻、中度焦虑抑郁症随机平行对照研究[J].实用中医内科杂志,2017,31(2):47-49.
[14]李爱歆,李鹏,李冬,等.黛力新用于心血管神经症80例的临床观察[J].黑龙江医药科学,2018,41(4):38-39,42.
[15]陈乐乐,岳增辉,朱小姗.针刺对单胺类神经递质及相关神经系统疾病的影响[J].辽宁中医药大学学报,2011,13(12):83-85.
[16]吴雪芬,郑雪娜,郭鑫,等.针刺对失眠大鼠5-HT及其受体、HPA轴相关激素影响的研究进展[J].中华中医药学刊,2018,36(1):127-129.